13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001931118
Total reported value
$158.4M
$158.4M
45 檔
47.1%
During the Q4 2025 filing period, Superstring Capital Management LP (CIK: 0001931118) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $158.4M across 45 reported positions.
In Q4 2025, Superstring Capital Management LP displayed an active expansion posture, initiating 29 new positions and adding to 5 existing holdings, outstripping position reductions.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | CDTX | Cidara Therapeutics Inc | Stock-Other | 10.06% | — | +24.30% | |
| 2 | 430 | Terns Pharmaceuticals Inc | Stock-Other | 9.60% | — | -43.80% | |
| 3 | URGN | UroGen Pharma Ltd. | Stock-Other | 9.01% | -0.53% | +717.13% | |
| 4 | COGT | Cogent Biosciences Inc | Stock-Other | 6.96% | +2.20% | +1.34% | |
| 5 | DVAX | Dynavax Technologies CORP | Stock-Other | 4.33% | — | — | |
| 6 | SION | Sionna Therapeutics Inc | Stock-Other | 3.98% | -2.29% | — | |
| 7 | IMVT | Immunovant Inc | Stock-Other | 3.93% | -1.28% | -15.43% | |
| 8 | AXSM | Axsome Therapeutics Inc | Stock-Healthcare | 3.66% | +6.98% | — | |
| 9 | SVRA | Savara Inc | Stock-Other | 3.21% | -2.39% | -23.97% | |
| 10 | BRD1EUR | Mind Medicine Mindmed Inc | Stock-Other | 3.05% | — | — | |
| 11 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 2.89% | -0.82% | EXIT | |
| 12 | OCUL | Ocular Therapeutix Inc | Stock-Other | 2.72% | — | — | |
| 13 | AM6 | Amicus Therapeutics Inc | Stock-Other | 2.69% | — | — | |
| 14 | CABA | Cabaletta Bio Inc | Stock-Other | 2.64% | +0.15% | +45.91% | |
| 15 | UTHR | United Therapeutics CORP | Stock-Healthcare | 2.47% | +0.25% | — | |
| 16 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 2.34% | +6.04% | NEW | |
| 17 | BLTE | Belite Bio Inc - Adr | Stock-Other | 2.12% | — | — | |
| 18 | DRUG | Bright Minds Biosciences Inc | Stock-Other | 1.98% | +0.66% | -12.37% | |
| 19 | ZLAB | Zai Lab Ltd-adr | Stock-Other | 1.86% | -1.84% | -1.88% | |
| 20 | ZBIO | Zenas Biopharma Inc | Stock-Other | 1.62% | — | -13.77% | |
| 21 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 1.54% | — | — | |
| 22 | AVTX | Avalo Therapeutics Inc | Stock-Other | 1.49% | — | -18.49% | |
| 23 | CAPR | Capricor Therapeutics Inc | Stock-Other | 1.49% | — | — | |
| 24 | PVLA | Palvella Therapeutics Inc | Stock-Other | 1.43% | — | — | |
| 25 | CLDX | Celldex Therapeutics Inc | Stock-Other | 1.28% | +2.68% | — | |
| 26 | ASMB | Assembly Biosciences Inc | Stock-Other | 1.19% | — | — | |
| 27 | ORIC | Oric Pharmaceuticals Inc | Stock-Other | 1.12% | +1.74% | +185.82% | |
| 28 | TARA | Protara Therapeutic Inc | Stock-Other | 1.03% | -0.16% | — | |
| 29 | TRVI | Trevi Therapeutics Inc | Stock-Other | 0.99% | +4.03% | — | |
| 30 | TYRA | Tyra Biosciences Inc | Stock-Other | 0.83% | — | — | |
| 31 | TVTX | Travere Therapeutics Inc | Stock-Other | 0.78% | -2.18% | EXIT | |
| 32 | VRDN | Viridian Therapeutics Inc | Stock-Other | 0.72% | — | — | |
| 33 | RZLT | Rezolute Inc | Stock-Other | 0.65% | — | — | |
| 34 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.58% | — | — | |
| 35 | SPRB | Spruce Biosciences Inc | Stock-Other | 0.57% | — | — | |
| 36 | AARD | Aardvark Therapeutics Inc | Stock-Other | 0.49% | — | — | |
| 37 | GMAB | Genmab A/s -sp Adr | Stock-Other | 0.48% | +3.70% | — | |
| 38 | PALI | Palisade Bio Inc | Stock-Other | 0.46% | — | — | |
| 39 | FULC | Fulcrum Therapeutics Inc | Stock-Other | 0.44% | — | — | |
| 40 | RARE | Ultragenyx Pharmaceutical In | Stock-Other | 0.39% | — | — | |
| 41 | PTN | Palatin Technologies Inc | Stock-Other | 0.28% | -0.45% | EXIT | |
| 42 | IVA | Inventiva SA - Adr | Stock-Other | 0.25% | — | — | |
| 43 | IPSC | Century Therapeutics Inc | Stock-Other | 0.25% | -0.19% | EXIT | |
| 44 | BMEA | Biomea Fusion Inc | Stock-Other | 0.17% | -0.22% | — | |
| 45 | ✓ | Entera Bio LTD | Stock-Other | 0.02% | — | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | URGN | UroGen Pharma Ltd. | +7.3% | +717.13% | Add |
| 2 | 430 | Terns Pharmaceuticals Inc | +3.8% | -43.80% | Trim |
| 3 | CDTX | Cidara Therapeutics Inc | +3.6% | +24.30% | Add |
| 4 | COGT | Cogent Biosciences Inc | +1.9% | +1.34% | Add |
| 5 | ORIC | Oric Pharmaceuticals Inc | +0.1% | +185.82% | Add |
| 6 | IPSC | Century Therapeutics Inc | 0% | — | Unchanged |
| 7 | BMEA | Biomea Fusion Inc | -0.3% | — | Unchanged |
| 8 | TVTX | Travere Therapeutics Inc | -0.5% | -29.10% | Trim |
| 9 | ZBIO | Zenas Biopharma Inc | -0.5% | -13.77% | Trim |
| 10 | TARA | Protara Therapeutic Inc | -0.5% | — | Unchanged |
| 11 | AVTX | Avalo Therapeutics Inc | -0.9% | -18.49% | Trim |
| 12 | CABA | Cabaletta Bio Inc | -0.9% | +45.91% | Add |
| 13 | DRUG | Bright Minds Biosciences Inc | -1.2% | -12.37% | Trim |
| 14 | SVRA | Savara Inc | -1.4% | -23.97% | Trim |
| 15 | IMVT | Immunovant Inc | -1.5% | -15.43% | Trim |
| 16 | ZLAB | Zai Lab Ltd-adr | -4.8% | -1.88% | Trim |
| 17 | DVAX | Dynavax Technologies CORP | — | NEW | New buy |
| 18 | SION | Sionna Therapeutics Inc | — | NEW | New buy |
| 19 | AXSM | Axsome Therapeutics Inc | — | NEW | New buy |
| 20 | BRD1EUR | Mind Medicine Mindmed Inc | — | NEW | New buy |
| 21 | ETNBGBP | 89bio Inc | — | EXIT | Sold out |
| 22 | TSHA | Taysha Gene Therapies Inc | — | NEW | New buy |
| 23 | JAZZ | Jazz Pharmaceuticals plc | — | EXIT | Sold out |
| 24 | OCUL | Ocular Therapeutix Inc | — | NEW | New buy |
| 25 | AM6 | Amicus Therapeutics Inc | — | NEW | New buy |
| 26 | UTHR | United Therapeutics CORP | — | NEW | New buy |
| 27 | BBIO | Bridgebio Pharma Inc | — | EXIT | Sold out |
| 28 | RVMD | Revolution Medicines Inc | — | NEW | New buy |
| 29 | SMMT | Summit Therapeutics Inc | — | EXIT | Sold out |
| 30 | BLTE | Belite Bio Inc - Adr | — | NEW | New buy |
| 31 | IQV | Iqvia Holdings Inc | — | EXIT | Sold out |
| 32 | REGN | Regeneron Pharmaceuticals | — | EXIT | Sold out |
| 33 | NKTR | Nektar Therapeutics | — | EXIT | Sold out |
| 34 | QNCX | Quince Therapeutics, Inc. | — | NEW | New buy |
| 35 | INSM | Insmed Inc | — | EXIT | Sold out |
| 36 | CAPR | Capricor Therapeutics Inc | — | NEW | New buy |
| 37 | BCAX | Bicara Therapeutics Inc | — | EXIT | Sold out |
| 38 | PVLA | Palvella Therapeutics Inc | — | NEW | New buy |
| 39 | CLDX | Celldex Therapeutics Inc | — | NEW | New buy |
| 40 | SNY | Sanofi-adr | — | EXIT | Sold out |
| 41 | ASMB | Assembly Biosciences Inc | — | NEW | New buy |
| 42 | QURE | uniQure N.V. | — | EXIT | Sold out |
| 43 | TECX | Tectonic Therapeutic Inc | — | EXIT | Sold out |
| 44 | TRVI | Trevi Therapeutics Inc | — | NEW | New buy |
| 45 | TYRA | Tyra Biosciences Inc | — | NEW | New buy |
| 46 | KROS | Keros Therapeutics Inc | — | EXIT | Sold out |
| 47 | SRRK | Scholar Rock Holding CORP | — | EXIT | Sold out |
| 48 | PTGX | Protagonist Therapeutics Inc | — | EXIT | Sold out |
| 49 | VRDN | Viridian Therapeutics Inc | — | NEW | New buy |
| 50 | RZLT | Rezolute Inc | — | NEW | New buy |
According to official SEC Form 13F filings, Superstring Capital Management LP reported a total U.S. public equity portfolio value of $158.4M across 45 disclosed positions in Q4 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including CDTX, 430, URGN) accounted for 47.1% of total reported equity market value during Q4 2025.
Top New Position Initiated
DVAX
市值: $8.1M
Top Position Liquidated / Trimmed
ETNBGBP
前期市值: $5.7M
During Q4 2025, Superstring Capital Management LP's top holdings by market value included CDTX (10.1%)、430 (9.6%)、URGN (9.0%). The largest single position, CDTX, represented 10.1% of total portfolio value.
In Q4 2025, Superstring Capital Management LP made 61 total portfolio adjustments, initiating 29 new buys, adding to 5 positions, trimming 8 holdings, and fully liquidating 19 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.